December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.17 -0.55 (-1.92%)
Streaming Delayed Price Updated: 12:36 PM EDT, Jul 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom? ↗
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Where Genmab Stands With Analysts ↗
Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter: 
Via Benzinga
News headline image
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial ↗
 
Via Benzinga
News headline image
Analyst Ratings for Genmab ↗
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings: 
Via Benzinga
News headline image
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
From Genmab
Via Business Wire
News headline image
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab
Via Business Wire
News headline image
Johnson & Johnson Stock: A Rare Bright Spot in the Market ↗
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. 
Via InvestorPlace
News headline image
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
From Genmab
Via Business Wire
News headline image
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study ↗
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) 
Via Benzinga
News headline image
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
News headline image
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗
 
Via Benzinga
News headline image
Best Biotech Stocks To Buy In 2022 ↗
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and... 
Via Talk Markets
News headline image
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
News headline image
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
News headline image
A Bearish Sign Looms Over Genmab's Chart ↗
If history is any guide, there may be trouble ahead for shares of Genmab (NASDAQ:GMAB). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
News headline image
Genmab A/S (GMAB) Q3 2021 Earnings Call Transcript ↗
GMAB earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.